We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

152 hedge funds and large institutions have $1.26B invested in Acorda Therapeutics in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 61 increasing their positions, 40 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 40

26% more capital invested

Capital invested by funds: $1B → $1.26B (+$258M)

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

1% more funds holding

Funds holding: 151 → 152 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

19% less call options, than puts

Call options by funds: $6.72M | Put options by funds: $8.28M

Holders
152
Holders Change
+1
Holders Change %
+0.66%
% of All Funds
3.79%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
61
Reduced
40
Closed
17
Calls
$6.72M
Puts
$8.28M
Net Calls
-$1.56M
Net Calls Change
+$10.6M

Top Buyers

1
PHS
PFM Health Sciences
California
+$32.1M
2
SCM
Scopia Capital Management
New York
+$27.5M
3
Invesco
Invesco
Georgia
+$15.4M
4
BBA
Baker Bros. Advisors
New York
+$11.4M
5
Deutsche Bank
Deutsche Bank
Germany
+$9.45M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$20.3M
2
CI
Cambiar Investors
Colorado
-$11.8M
3
GTC
Ghost Tree Capital
New York
-$7.88M
4
State Street
State Street
Massachusetts
-$6.39M
5
USAA
United Services Automobile Association
Texas
-$4.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Scopia Capital Management
New York
$200M +$27.5M +10,424 +17%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$165M -$29K -11 -0%
BlackRock
3
BlackRock
New York
$149M -$3.02M -1,148 -2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$101M -$1.06M -401 -1%
PHS
5
PFM Health Sciences
California
$95.8M +$32.1M +12,201 +57%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$62.8M +$6.21M +2,359 +12%
State Street
7
State Street
Massachusetts
$51.7M -$6.39M -2,426 -12%
Invesco
8
Invesco
Georgia
$29.9M +$15.4M +5,838 +124%
Northern Trust
9
Northern Trust
Illinois
$24.9M +$3.4M +1,292 +17%
ClearBridge Investments
10
ClearBridge Investments
New York
$22.4M +$7.9K +3 +0%
RCM
11
RA Capital Management
Massachusetts
$21.3M – – –
HEC
12
Hudson Executive Capital
New York
$21.1M +$2.64M +1,004 +16%
Macquarie Group
13
Macquarie Group
Australia
$16.2M +$1.82M +689 +14%
Deutsche Bank
14
Deutsche Bank
Germany
$16M +$9.45M +3,588 +175%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$13.3M -$1.2M -457 -9%
Norges Bank
16
Norges Bank
Norway
$13.3M – – –
Bank of New York Mellon
17
Bank of New York Mellon
New York
$13.2M +$274K +104 +2%
Goldman Sachs
18
Goldman Sachs
New York
$12.8M +$119K +45 +1%
JP Morgan Chase
19
JP Morgan Chase
New York
$12.7M +$4.49M +1,705 +60%
BBA
20
Baker Bros. Advisors
New York
$12.3M +$11.4M +4,329 New
SIM
21
Spark Investment Management
New York
$10.8M +$524K +199 +6%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$10.2M -$511K -194 -5%
Principal Financial Group
23
Principal Financial Group
Iowa
$8.35M -$68.5K -26 -0.9%
CI
24
Cambiar Investors
Colorado
$7.63M -$11.8M -4,488 -63%
Ameriprise
25
Ameriprise
Minnesota
$7.38M -$856K -325 -11%
1
2 3 4 5

ACOR Hedge Fund Activity: Q3 2017 in Review

152 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2017, worth a combined $1.26B — up 26% from $1B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ACOR positions and 17 closed out — a net gain of 1 holder — while 61 added to existing stakes and 40 trimmed.

The largest buyer was PFM Health Sciences, adding an estimated $32.1M. The largest seller was Citadel Advisors, cutting an estimated $20.3M.

  • 152 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2017, up from 151 in Q2 2017.
  • Funds reported $1.26B of Acorda Therapeutics stock for Q3 2017, up 26% quarter-over-quarter.
  • 18 funds opened new Acorda Therapeutics positions in Q3 2017 and 17 closed out, a net change of +1 holder.
  • The largest Acorda Therapeutics buyer in Q3 2017 was PFM Health Sciences, an estimated $32.1M added.
  • The largest Acorda Therapeutics seller in Q3 2017 was Citadel Advisors, an estimated $20.3M sold.

Based on aggregated 13F filings for Q3 2017.